Suppliers and packagers for PURINETHOL

PURINETHOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Stason Pharms	PURINETHOL	mercaptopurine	TABLET;ORAL	009053	NDA	Florida Pharmaceutical Products, LLC	71921-150-02	25 TABLET in 1 BOTTLE (71921-150-02)	2026-01-30
Stason Pharms	PURINETHOL	mercaptopurine	TABLET;ORAL	009053	NDA	Florida Pharmaceutical Products, LLC	71921-150-25	250 TABLET in 1 BOTTLE (71921-150-25)	2026-01-30

Purinethol (Mercaptopurine) Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the global supply chain for purinethol (mercaptopurine), a critical antimetabolite used in treating acute lymphoblastic leukemia (ALL) and Crohn's disease. The analysis focuses on key manufacturers, active pharmaceutical ingredient (API) suppliers, and geographical distribution of production.

Who Are the Primary Manufacturers of Mercaptopurine APIs?

The manufacturing of mercaptopurine API is concentrated among a limited number of global pharmaceutical chemical companies. These entities are responsible for synthesizing the active ingredient that is subsequently formulated into finished dosage forms by drug product manufacturers. Key players identified in API production include:

• Abraxis Pharmaceutical Products: A significant player in the generic API market, Abraxis is involved in the production of mercaptopurine.
• Teva Pharmaceutical Industries Ltd.: As one of the world's largest generic drug manufacturers, Teva produces a range of APIs, including mercaptopurine, for its internal use and for sale to other formulators.
• Mylan N.V. (now Viatris): Prior to its merger with Pfizer's Upjohn division to form Viatris, Mylan was a notable producer of mercaptopurine API. Viatris continues this legacy.
• Hikma Pharmaceuticals PLC: Hikma is a global pharmaceutical company with manufacturing capabilities that include the production of critical oncology APIs.
• Sun Pharmaceutical Industries Ltd.: India-based Sun Pharma is a major generic pharmaceutical producer with a broad API portfolio, which includes mercaptopurine.

These companies operate large-scale chemical synthesis facilities, often in regions with established pharmaceutical manufacturing infrastructure and regulatory compliance.

What are the Key Geographical Hubs for Mercaptopurine API Production?

The production of mercaptopurine API is geographically diverse but shows a significant concentration in specific regions, primarily driven by cost efficiencies, regulatory environments, and established pharmaceutical manufacturing expertise.

• India: This country is a dominant global supplier of pharmaceutical APIs, including mercaptopurine. Numerous Indian companies have invested heavily in R&D and manufacturing capacity, allowing them to produce high-quality APIs at competitive prices. Major API hubs in India include Gujarat and Maharashtra.
• China: China is another leading global supplier of pharmaceutical ingredients. While specific mercaptopurine API production details are less publicly disclosed compared to Indian counterparts, Chinese manufacturers play a crucial role in the global API supply chain across various therapeutic areas. Key manufacturing provinces include Jiangsu and Zhejiang.
• Europe: Some European countries, particularly those with established chemical and pharmaceutical industries like Germany and Italy, also host API manufacturers. These facilities often focus on specialized or high-purity APIs and adhere to stringent European Medicines Agency (EMA) standards.
• North America: While less dominant in bulk API manufacturing compared to Asia, some North American companies may produce mercaptopurine API or have significant contract manufacturing operations within the region, often for localized supply chains or specific regulatory requirements.

The prevalence of Indian and Chinese manufacturers reflects their ability to scale production, leverage cost advantages, and navigate complex global regulatory landscapes.

What is the Regulatory Landscape Governing Mercaptopurine API Production?

The production of mercaptopurine API is subject to strict regulatory oversight by health authorities in major markets to ensure product quality, safety, and efficacy. Key regulatory frameworks include:

• U.S. Food and Drug Administration (FDA): API manufacturers supplying the U.S. market must comply with FDA's Current Good Manufacturing Practices (CGMP). Facilities are subject to FDA inspections. Drug Master Files (DMFs) are often submitted to the FDA by API manufacturers to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
• European Medicines Agency (EMA): For the European Union market, API manufacturers must adhere to EU GMP guidelines. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often sought to demonstrate compliance with European Pharmacopoeia standards and facilitate regulatory approval for finished drug products.
• Other National Regulatory Bodies: Authorities in other countries, such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Health Canada, have their own GMP requirements and inspection processes.

Manufacturers must maintain robust quality management systems, conduct rigorous analytical testing, and ensure traceability throughout the production process. Compliance audits and site inspections are routine.

What Are the Typical Specifications and Quality Standards for Mercaptopurine API?

Mercaptopurine API must meet specific quality and purity standards defined by major pharmacopoeias to ensure its suitability for pharmaceutical use. These standards dictate acceptable levels of impurities, physical characteristics, and assay.

• Assay: The mercaptopurine content is typically required to be within a narrow range, commonly 98.0% to 102.0% on an anhydrous basis, as specified by pharmacopoeias.
• Impurities: Limits are set for related substances, including specific known impurities and total impurities. For example, purine, 6-mercaptopurine monohydrate, and other degradation products must be controlled below defined thresholds.
• Loss on Drying/Water Content: Specifications address the acceptable moisture content, as mercaptopurine can exist in hydrated forms.
• Heavy Metals: Limits are imposed on the presence of heavy metals, which are toxic contaminants.
• Residual Solvents: The levels of residual solvents used during the synthesis process must be controlled within acceptable limits, as defined by ICH guidelines.
• Physical Characteristics: Particle size distribution, appearance (e.g., yellow crystalline powder), and solubility are also specified.

These standards are detailed in pharmacopoeial monographs, such as the United States Pharmacopoeia (USP) and the European Pharmacopoeia (Ph. Eur.). Manufacturers must demonstrate consistent adherence to these specifications through validated analytical methods.

What Are the Primary Uses and Market Dynamics for Mercaptopurine?

Mercaptopurine is a cornerstone therapy in specific oncological and immunological indications, driving consistent demand for its API.

• Acute Lymphoblastic Leukemia (ALL): Mercaptopurine, often in combination with other chemotherapeutic agents, is a standard treatment for childhood ALL and has been for decades. It is a maintenance therapy drug.
• Crohn's Disease: In inflammatory bowel disease, mercaptopurine is used as an immunosuppressant to manage moderate to severe cases, particularly when other treatments have failed.

The market for mercaptopurine is characterized by:

• Generic Status: Mercaptopurine is a well-established, off-patent drug. The market is dominated by generic manufacturers, leading to price competition.
• Stable Demand: While not a blockbuster drug, the indications for mercaptopurine (ALL, Crohn's) represent conditions with stable or growing patient populations globally, ensuring consistent demand.
• Supply Chain Vulnerability: As with many older, essential medicines, the generic API market can be susceptible to supply disruptions due to manufacturing issues, raw material shortages, or economic factors affecting specific producers.
• Critical Medicine Status: Mercaptopurine is often classified as a critical medicine by health organizations, highlighting its importance and the need for uninterrupted supply.

The relatively small number of API suppliers for mercaptopurine means that any disruption at one of these facilities can have a significant impact on the global supply chain.

Who are the Major Finished Dosage Formulators of Mercaptopurine Products?

Finished dosage formulators purchase mercaptopurine API from suppliers and then manufacture the final drug product in various strengths and forms, typically oral tablets. Key global formulators include:

• Teva Pharmaceutical Industries Ltd.: A major provider of generic pharmaceuticals worldwide, Teva manufactures and markets mercaptopurine tablets.
• Hikma Pharmaceuticals PLC: Through its generics division, Hikma supplies mercaptopurine tablets to various markets.
• Sun Pharmaceutical Industries Ltd.: Similar to its API production, Sun Pharma also formulates finished mercaptopurine products.
• Viatris Inc.: The combined entity of Mylan and Pfizer's Upjohn division, Viatris, continues to offer mercaptopurine formulations.
• Accord Healthcare Ltd.: Part of the Intas Pharmaceuticals group, Accord is a significant player in generic drug distribution and formulation across Europe and other regions.
• Aspen Pharmacare Holdings Limited: Aspen is a global pharmaceutical company with a strong presence in generic medicines, including oncology drugs like mercaptopurine, particularly in Australia and South Africa.

These companies operate under strict GMP regulations for drug product manufacturing, ensuring the quality, safety, and consistency of the final medicine administered to patients. They rely on a stable supply of high-quality mercaptopurine API.

What are the Potential Supply Chain Risks and Mitigation Strategies?

The supply chain for mercaptopurine, like many essential generic medicines, faces several inherent risks. Proactive management is crucial for ensuring consistent availability.

Supply Chain Risks:

• Single-Source Dependence: While multiple API manufacturers exist, the market can become concentrated if some producers exit or face production challenges, leading to over-reliance on a few suppliers.
• Geopolitical Instability: Concentration of API production in specific geographic regions (e.g., India, China) makes the supply chain susceptible to disruptions from political events, trade disputes, or natural disasters in those areas.
• Raw Material Shortages: The synthesis of mercaptopurine relies on precursor chemicals. Shortages or price volatility of these raw materials can impact API production costs and availability.
• Quality Compliance Issues: A significant manufacturing defect or recall at a major API supplier can halt production and create a critical shortage. Regulatory non-compliance can lead to facility shutdowns.
• Logistical Challenges: Transportation disruptions, port congestion, or increased shipping costs can delay the movement of API from manufacturers to formulators.
• Economic Viability of Older Drugs: For some older, lower-margin drugs like mercaptopurine, economic pressures might lead manufacturers to reallocate resources or discontinue production if profitability declines.

Mitigation Strategies:

• Dual/Multi-Sourcing: Finished drug product manufacturers should aim to qualify and maintain relationships with at least two API suppliers to reduce dependence on a single source.
• Geographic Diversification: Sourcing API from manufacturers located in different geographical regions can mitigate risks associated with localized disruptions.
• Long-Term Supply Agreements: Establishing longer-term contracts with API suppliers can help secure pricing and ensure supply commitments, fostering greater stability.
• Inventory Management: Maintaining strategic buffer stocks of API at the finished product manufacturing sites can provide a cushion against short-term supply disruptions.
• Supplier Audits and Due Diligence: Regular, thorough audits of API manufacturers' quality systems, regulatory compliance, and financial health are essential.
• Active Regulatory Monitoring: Staying abreast of regulatory changes and potential enforcement actions affecting key API suppliers is crucial.
• Supply Chain Mapping and Transparency: Understanding the entire supply chain, including critical raw material suppliers to API manufacturers, can help identify potential bottlenecks upstream.
• Collaboration with Health Authorities: Engaging with regulatory bodies and sharing supply chain intelligence can facilitate coordinated responses during shortages.

Key Takeaways

The global supply chain for mercaptopurine (purinethol) API is characterized by a concentrated manufacturing base, primarily in India and China, serving a stable but essential demand driven by its critical role in treating ALL and Crohn's disease. Key API suppliers include Teva, Mylan/Viatris, Sun Pharma, Hikma, and Abraxis. These manufacturers must adhere to stringent FDA and EMA GMP regulations. The API must meet pharmacopoeial standards for assay, impurities, and other quality attributes. Finished dosage forms are produced by major generic pharmaceutical companies such as Teva, Hikma, Sun Pharma, and Viatris. Supply chain risks, including single-sourcing, geopolitical instability, and quality compliance issues, necessitate robust mitigation strategies such as dual-sourcing, geographic diversification, and proactive supplier management.

Frequently Asked Questions

1. How does the regulatory status of mercaptopurine (off-patent) impact its supply chain compared to newer, patented drugs?

As an off-patent drug, mercaptopurine faces intense price competition among generic manufacturers. This can lead to lower profit margins for API producers, potentially making them less incentivized to invest in expanding capacity or maintaining high inventory levels. Consequently, the supply chain can be more vulnerable to disruptions if a manufacturer exits the market or faces production issues, as the economic incentive to replace them might be lower than for a high-margin patented drug.

2. What is the typical lead time for sourcing mercaptopurine API from major suppliers in India or China?

Typical lead times for sourcing mercaptopurine API from major suppliers in India or China can range from 8 to 16 weeks from order placement to delivery, assuming standard order volumes and current production schedules. However, this lead time can fluctuate significantly based on the supplier's existing order book, raw material availability, production batch sizes, and any required quality control or testing periods. Urgent or unusually large orders may incur longer lead times.

3. Are there any publicly disclosed instances of significant global mercaptopurine API shortages in the past five years?

Publicly disclosed significant global shortages of mercaptopurine API are not extensively documented in recent years, but the drug is frequently listed on national essential medicines lists and flagged for potential supply vulnerabilities. Incidents of drug shortages often arise from specific product formulations rather than the API itself. However, reports from organizations like the FDA's drug shortage list and the American Society of Health-System Pharmacists (ASHP) occasionally indicate temporary issues or low stock levels for mercaptopurine tablets, which can indirectly signal API supply chain pressures or formulation-specific challenges.

4. How do impurity profiles of mercaptopurine API from different suppliers compare, and what are the implications for drug product manufacturers?

While all API suppliers must meet pharmacopoeial standards, the specific impurity profiles can vary between manufacturers due to differences in synthesis routes, purification processes, and analytical testing capabilities. Drug product manufacturers must validate their formulations with API from each approved supplier to ensure that the final drug product continues to meet all quality and safety specifications. Significant deviations in impurity profiles, even if within pharmacopoeial limits, can necessitate re-evaluation of the finished product's stability and efficacy.

5. What is the role of contract manufacturing organizations (CMOs) in the mercaptopurine supply chain, particularly for API synthesis?

CMOs play a significant role in the mercaptopurine API supply chain, especially for smaller or mid-sized pharmaceutical companies that may not have their own large-scale API manufacturing facilities. These CMOs, often located in India and China, specialize in chemical synthesis and possess the necessary infrastructure and expertise to produce APIs like mercaptopurine according to stringent GMP standards. They offer flexibility and scalability, allowing drug product manufacturers to manage their supply chains more efficiently and reduce capital investment in manufacturing plants.

Citations

[1] United States Pharmacopeia. (n.d.). Mercaptopurine. In United States Pharmacopeia–National Formulary. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the European Pharmacopoeia. [3] U.S. Food & Drug Administration. (n.d.). Drug Master Files. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R6). [5] World Health Organization. (2019). Critically important medicines for public health: WHO Fourth Essential Medicines List (EML) analysis. [6] Various pharmaceutical company annual reports and investor presentations (e.g., Teva Pharmaceutical Industries, Hikma Pharmaceuticals, Sun Pharmaceutical Industries, Viatris Inc., Aspen Pharmacare). [7] Pharmaceutical Technology. (Various dates). Industry news and market analysis related to API manufacturing and drug shortages.